For research use only. Not for therapeutic Use.
Tuvonralimab（Cat No.:I042127）is an investigational monoclonal antibody designed to target and inhibit the TIGIT (T cell immunoreceptor with Ig and ITIM domains) receptor. TIGIT plays a role in suppressing the immune system’s ability to attack tumor cells, so by blocking it, Tuvonralimab aims to enhance the body’s immune response against cancer. It is being studied for use in combination with other therapies, such as PD-1 inhibitors, in treating various cancers, including non-small cell lung cancer and melanoma. Ongoing clinical trials are evaluating its safety, efficacy, and potential to improve patient outcomes.
| Catalog Number | I042127 |
| CAS Number | 2417649-44-4 |
| Purity | ≥95% |
